Collaboration in healthcare teams is becoming the “go-to” strategy for solving some of the thorniest problems facing the industry. While critical to success, collaboration is no easy task. Clinical care and medical research have become more complex and specialized, requiring multi-disciplinary teams to come together often from multiple organizations. Healthcare systems, biotechnology, and pharmaceutical companies, and health technology start-ups are forming, merging, and/or being acquired at an increased pace. Because of this, administrative, clinical, and executive teams are being tasked with collaborating in new and different ways.
At The Leadership Development Group (TLD Group) we believe workplaces, especially those in the health ecosystem, have entered a pivotal moment in time. COVID-19 has further heightened challenges around employee mental health and well-being in workplaces. Intrigued by the topic, we enlisted the help of expert Z. Colette Edwards, MD, MBA, Humana’s National Medical Director, Associate Health and Well-Being.
In this blog, Colette shares her insights for leaders looking to open the door to more conversations around stress and mental health within their organizations.
May is Mental Health Awareness Month and The Leadership Development Group (TLD Group) took an opportunity to interview Laura Marsh, MD, Executive Director, Mental Health Care Line for the Veteran Affairs Medical Center in Houston, TX. Dr. Marsh, a geriatric psychiatrist and a neuropsychiatrist whose background is in neurological conditions with psychiatric complications, is also Professor, Menninger Department of Psychiatry, Baylor College of Medicine in Houston.
In this blog, Dr. Marsh shares her recommendations for leaders looking to move the needle on mental health initiatives within their own communities. Below is a preview of the longer interview.
We are fortunate to have an advisory board, comprised of multi-sector industry leaders from a variety of disciplines, to guide our strategy and growth. We have created the “Meet the Advisory Board” series as a way to introduce you to these talented leaders and learn about their perspectives on leadership and cross-sector collaboration.
In this interview meet Advisory Board member Kent Bottles, MD. Kent is our resident futurist and a thought-leader in healthcare policy and payment reform. At TLD Group we turn to him often for his perspective on health industry transformation and change.
Interview with TLD Group Advisory Board Member- Kent Bottles
We are fortunate to have an advisory board, comprised of multi-sector industry leaders from a variety of disciplines, to guide our strategy and growth. We have created the “Meet the Advisory Board” series as a way to introduce you to these talented leaders and learn about their perspectives on leadership and cross-sector collaboration.
In this inaugural interview meet Advisory Board Chair Bob Sachs, PhD. Bob has a passion for leadership development and offers timely advice for today's leaders.
Interview with TLD Group Advisory Board Chair- Bob Sachs
Before the World Health Organization (WHO) declared COVID-19 a pandemic, pharmaceutical companies like Pfizer, Moderna, Johnson & Johnson and Gilead were often tagged as “big pharma” putting profit before purpose.
Now, one year later, pharmaceutical companies are being praised for their positive impact resulting from the speed at which they were capable of producing FDA-approved treatments and vaccines for COVID-19.
Through its ingenuity, strategic leadership and nimble pipeline management practices, the pharmaceutical industry is meeting a deep and drastic human need: to keep ourselves and our loved ones healthy and alive.
The end of Haven Healthcare
When the formation of Haven Healthcare was announced in 2018, Jamie Dimon, Chairman and CEO of JP Morgan, one of the sponsoring organizations (Amazon and Berkshire Hathaway were the other two) said, "The three of our companies have extraordinary resources, and our goal is to create solutions that benefit our U.S. employees, their families and, potentially, all Americans."
What will happen to healthcare in the United States when the election is over, the Supreme Court has heard arguments to declare the ACA unconstitutional, the coronavirus is still infecting Americans, and the political landscape is a little less uncertain? No one knows for sure, but Dr. Kent Bottles certainly has his opinions and provides them by looking into his crystal ball and analyzing perspectives from key opinion leaders in the field. As Kent likes to quote, "Prediction is very difficult, especially if it's about the future" (Nobel Physics laureate Nils Bohr) and "It is far better to foresee even without certainty than not to foresee at all" (Henri Poincare). In this webinar Kent covers:
1. How the ACA will change in 2021.
2. How the COVID-19 crisis will transform healthcare and society in the future.
3. How the new Congress will legislate in the healthcare arena.
4. How the new political landscape will affect hospitals, doctors, patients, and pharmaceutical companies.
It's no secret that the US health system is in desperate need of repair. Structural inequities such as housing and food insecurity, air and water pollution, and access to educational and economic opportunities — known to the medical community as social determinants have been linked to disparate health outcomes for years. However, never in recent history have we so acutely and rapidly felt their affects as we have during the COVID-19 pandemic. United around the common purpose to improve overall population health, industry leaders must harness their collective power and influence to champion changes that will benefit the health of our nation.
At TLD Group, we believe that we've arrived at a pivotal moment in time, one that we hope will inspire America to engage in a conversation around how we as individuals and organizations and as a nation can and must do better. Centuries of inequality and racism have culminated into acutely horrific consequences for Black Americans in 2020.
